H2020 grant success!

The MCDS-Therapy project has been awarded €5,700,000 from the European Union’s Horizon 2020 fund.

The MCDS-Therapy project has received the fantastic news that our application to the European Union’s Horizon 2020 fund has been successful. An award of €5,700,000 was confirmed in December 2017, and was met with delight by all our global partners. The grant was awarded from H2020’s ‘SC1-PM-08-2017 New Therapies for Rare Diseases’ call for projects, which is part of their Research and Innovation action.

The grant will be used to fund the observational study and clinical trial in all trial sites, biomarker discovery research, health economic research, patient engagement, and public and patient engagement for the MCDS-Therapy project. We are delighted that over 20 years of hard work in pre-clinical research, as well as the potential of the project to deliver an effective treatment to patients, was recognised by the European Union grant. Of the 127 projects submitted to this particular H2020 call, only 10, including MCDS-Therapy, were funded. Without this funding, the multi-site and in-depth research we had planned would not have been able to take place.

We would like to say a huge thank you to the Horizon 2020 team for their financial support, and to everyone involved in our application. The whole consortium is excited to get started.